Limited data concerning ICIs as a single-agent therapy has come from retrospective studies reporting that the ORR for patients with advanced HER2-mutant lung cancer ranges from 7.4 to 29%, with a PFS ranging from 1.8 to 3.4 months [108,109,110,111,112]. Here, ERBB2 is linked to lung cancer.